# D-Pharm

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/d-pharm

- Industry: Pharmaceuticals
- Headquarters: Rehovot, Israel
- Website: www.dpharm.com
- Total disclosed funding: $30M
- Latest round: Series A (Sep 30, 2001)
- Investors on record: 10

## About

D-Pharm LTD. is a company specializing in premium domain names and brand development services, enhancing the online presence of businesses through innovative branding solutions and AI-powered tools.D-Pharm LTD. focuses on the sale of premium domain names and branding services. The company is headquartered in Rehovot, Israel. It has raised a total of USD 10.00 mn through various funding rounds, with the latest round occurring recently, attracting investors such as Care Capital, Clal Biotechnology, Israel Healthcare Ventures, Pitango Venture Capital, and Polar Communication. John D serves as the CEO.D-Pharm specializes in the sale of premium domain names, including the notable DPharm.com, currently available for purchase. The company provides a diverse range of expertly curated, brandable domains designed for startups and established brands. Additionally, they offer AI-powered branding tools, such as name generators and logo design services. Their offerings also include targeted surveys and trademark assistance to address key business needs in the digital marketplace, focusing on regions robust in technology and e-commerce, including North America, Europe, and parts of Asia.D-Pharm generates revenue primarily through domain sales and associated branding services, predominantly in a B2B structure. They target businesses ranging from startups to larger enterprises needing high-quality domain names and branding solutions. The transaction structure involves direct purchases of domains, which may include ancillary services like trademark registration and branding consultations. Pricing for domain names varies significantly based on demand and characteristics, while branding services are offered through tiered pricing plans, accommodating client needs across different service offerings.D-Pharm LTD. plans to leverage recent funding of USD 10.00 mn to enhance its product offerings and expand into new markets. The company aims to introduce new AI-powered branding solutions by the end of 2024, targeting expansion in emerging markets across Asia and Europe. This strategy is aligned with their recent investment round, which has facilitated the development of additional products and a broader geographic reach, signaling a robust approach towards future growth.

## Funding rounds

- Series A, Sep 30, 2001, $30M — Care Capital, RHO, Vertex Ventures Israel, Gemini Israel Ventures, Challenge Fund, Denali Ventures, Quintiles Transnational Corporation, Clal Biotechnology, Morgan Stanley Expansion Capital, Group 11

## Investors

- Care Capital (https://capitalatlas.ai/funds/care-capital) — Series A
- RHO (https://capitalatlas.ai/funds/rho) — Series A
- Vertex Ventures Israel (https://capitalatlas.ai/funds/vertex-ventures-israel) — Series A
- Gemini Israel Ventures (https://capitalatlas.ai/funds/gemini-israel-ventures) — Series A
- Challenge Fund (https://capitalatlas.ai/funds/challenge-fund) — Series A
- Denali Ventures (https://capitalatlas.ai/funds/denali-ventures) — Series A
- Quintiles Transnational Corporation — Series A
- Clal Biotechnology (https://capitalatlas.ai/funds/clal-biotechnology) — Series A
- Morgan Stanley Expansion Capital (https://capitalatlas.ai/funds/morgan-stanley-expansion-capital) — Series A
- Group 11 (https://capitalatlas.ai/funds/group-11) — Series A